Market Overview

UPDATE: BMO Capital Markets Initiates AbbVie at Outperform on Yield, Humira Support

Related ABBV
AbbVie Inc Spikes On Reported End-Run Around Inversion Rules
Inversion Crackdown Leaves Several Deals In Limbo
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

BMO Capital Markets initiated coverage on AbbVie (NYSE: ABBV) with an Outperform rating and a $39 price target.

BMO Capital Markets commented, "We would be opportunistic buyers of ABBV in the low- to mid-$30s range. We believe the dividend yield (4.6%-5.3%) should support the stock at these levels. In short, Humira should give AbbVie plenty of time and cash to 1) develop its economically attractive specialty focused pipeline (e.g., Hep-C oral regimen expected in 2015), 2) return 50%-60% of its FCF to shareholders as dividends and share buybacks, and 3) explore longer-term strategic options.

AbbVie closed at $34.16 on Monday.

Latest Ratings for ABBV

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsOutperform
Jul 2014UBSUpgradesNeutralBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters